/Investor DB

New Leaf Venture Partners — 2018 Investments

5 investments dated 2018 · listed companies and verified rows first · show all

Rallybio, LLCrallybio.comin𝕏NASDAQ: RLYBApr 2018

Rallybio is a clinical-stage biotech company developing therapies for people with severe and rare diseases, with a pipeline focused on complement dysregulation and hematology.

BiotechHealthtechNew Haven, US

Stephen Uden(Founder)inMartin W. Mackay(Chairman of the Board of Directors)inJon(Chief Financial Officer)

Co-investors5AM VenturesCanaan PartnersConnecticut InnovationsF-Prime CapitalMitsui Global InvestmentPivotal Life Sciences+2 more

CuraSen Therapeuticscurasen.cominOct 2018✓ verified

CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling.

BiotechHealthtechSan Carlos, US

Anthony Ford(Executive Officer, Director)inBenjamin Potter(Executive Officer)Henry Skinner(Director)Liam Ratcliffe(Director)in

BoardRon Hunt(Director)inLoretta Tse, Ph.D.(Director)

Co-investorsAlta PartnersLongitude CapitalJohnson & Johnson Innovation – JJDCPappas CapitalChiesi VenturesPappas Capital

ReViralreviral.co.ukAug 2018 · $55M

Reviral operates an affiliate review site that ranks and reviews online casinos not registered with the UK's GamStop self-exclusion scheme, comparing licences, bonuses, wagering terms, payout speeds, and payment methods.

ConsumerMedia & Entertainment

Co-investorsAndera PartnersBrace PharmaOrbiMedWellcome Trust

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Braeburn PharmaceuticalsNeurana Pharmaceuticals

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.